P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
Dysregulation of the EGFR family member HER2 (human epidermal growth factor receptor 2) plays an important role in many cancers. HER2 exon 20 in-frame insertion mutations occur in 2−4% of non-small cell lung carcinomas (NSCLC). Despite current HER2-directed treatments, no approved therapies exist for patients with cancers harboring HER2 mutations. Unlike other activating mutations, exon 20…
